- 1 Title: Global Menstrual Cycle Symptomatology as Reported by Users of a Menstrual Tracking
- 2 Mobile Application
- 3 Alessandra J Ainsworth,  $MD^{1}$
- 4 Kimberly Peven,  $PhD^2$
- 5 Ryan Bamford, MSc<sup>2</sup>
- 6 Liudmila Zhaunova,  $PhD^2$
- 7 Rodion Salimgaraev,  $MD^2$
- 8 Carley Prentice,  $BA^2$
- 9 Aidan Wickham,  $PhD^2$
- 10 Adam Cunningham,  $PhD^2$
- 11 Frederick Goddard,  $PhD^2$
- 12 Sonia Ponzo, PhD<sup>2, 3</sup>
- 13 Samir N Babayev,  $MD^{1}$
- 14
- <sup>1</sup> Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and
- 16 Infertility, Mayo Clinic, Rochester, Minnesota
- <sup>2</sup> Flo Health UK Limited, London, United Kingdom
- <sup>3</sup> University College London, Institute of Health Informatics
- 19
- 20 Address Correspondence to: Samir N. Babayev, MD
- 21 Mayo Clinic
- 22 200 First Street SW
- 23 Rochester, MN 55905
- 24 (507) 284-9792

#### Ainsworth et al, 2

## 25 <u>Babayev.samir@mayo.edu</u>

26

## 27 Abstract

28 Background: Although a shared experience throughout the world, menstrual symptomatology is

29 underreported and often misunderstood, by both individuals who menstruate and their providers.

30 This study aimed to investigate symptomatology throughout the menstrual cycle, including the

31 frequency of symptoms reported for each phase of the cycle and the relationship between

32 symptoms.

33 Methods: This study included self-reported cycle information and symptoms during ovulatory

34 menstrual cycles in mobile application users. Symptom frequency was described overall, by

35 phase, and by day. Relationships between symptoms were examined through correlation

36 coefficients and term frequency-inverse document frequency analysis.

37 Results: 437,577 unique users and 896,051 unique cycles were included in the analysis. Somatic 38 symptoms were most frequently reported, logged in 88.3% of cycles. Of the total symptoms 39 logged, somatic, gastrointestinal, and negative mood symptoms were most prevalent in the late 40 luteal and bleeding days. In contrast, positive mood and discharge were most reported in the 41 fertile window. Mood symptoms were highly correlated with each other (energetic mood and 42 happy mood r=0.62, anxious mood and obsessive thoughts r=0.60). Fatigue was highly 43 correlated with somatic and gastrointestinal symptoms such as bloating (r=0.62), headache 44 (r=0.60), backache (r=0.58), and nausea (r=0.55).

Conclusions: Menstrual cycle-related symptoms are very common and vary throughout the
menstrual cycle. While negative symptoms, including pain, bloating, and negative mood, are

47	most commonly reported, women also report positive symptoms, such as energetic and happy
48	mood. Self-reported data from cycle tracking and health apps can improve our understanding of
49	the prevalence and variability of menstrual-related symptoms.
50	Trial Designed and Made and Sciences
51	<b>I rial kegistration</b> : Not applicable.
52 53	Key Words: Menstrual symptoms, Menstruation, Period Tracking, Mobile Application
54 55	Plain English Summary: Our study includes data collected from users of a menstrual tracking
56	application. We found that menstrual symtpoms are common, throughout the menstrual cycle,
57	and include both positive and negative mood and physical symptoms. This large data set may
58	help to normalize menstrual symptoms and provide a basis for future research and understanding.
59	Background:
59 60	<b>Background:</b> Although a shared experience by women and people who menstruate throughout the
59 60 61	Background: Although a shared experience by women and people who menstruate throughout the world, menstruation represents an area of health often ignored and misunderstood by both
59 60 61 62	Background: Although a shared experience by women and people who menstruate throughout the world, menstruation represents an area of health often ignored and misunderstood by both patients and healthcare providers. While many individuals experience menstruation without
59 60 61 62 63	Background: Although a shared experience by women and people who menstruate throughout the world, menstruation represents an area of health often ignored and misunderstood by both patients and healthcare providers. While many individuals experience menstruation without significant symptoms, others endure pain and many other somatic, gastrointestinal, and mood
59 60 61 62 63 64	Background: Although a shared experience by women and people who menstruate throughout the world, menstruation represents an area of health often ignored and misunderstood by both patients and healthcare providers. While many individuals experience menstruation without significant symptoms, others endure pain and many other somatic, gastrointestinal, and mood symptoms which vary throughout the cycle. Dysmenorrhea affects 45-95% of menstruating
59 60 61 62 63 64 65	Background: Although a shared experience by women and people who menstruate throughout the world, menstruation represents an area of health often ignored and misunderstood by both patients and healthcare providers. While many individuals experience menstruation without significant symptoms, others endure pain and many other somatic, gastrointestinal, and mood symptoms which vary throughout the cycle. Dysmenorrhea affects 45-95% of menstruating individuals, with wide variation due to differing definitions of the condition (1). Compared with
59 60 61 62 63 64 65 66	Background: Although a shared experience by women and people who menstruate throughout the world, menstruation represents an area of health often ignored and misunderstood by both patients and healthcare providers. While many individuals experience menstruation without significant symptoms, others endure pain and many other somatic, gastrointestinal, and mood symptoms which vary throughout the cycle. Dysmenorrhea affects 45-95% of menstruating individuals, with wide variation due to differing definitions of the condition (1). Compared with pain-free phases of their cycles, those suffering from dysmenorrhea experience reduced quality
59 60 61 62 63 64 65 66 67	Background: Although a shared experience by women and people who menstruate throughout the world, menstruation represents an area of health often ignored and misunderstood by both patients and healthcare providers. While many individuals experience menstruation without significant symptoms, others endure pain and many other somatic, gastrointestinal, and mood symptoms which vary throughout the cycle. Dysmenorrhea affects 45-95% of menstruating individuals, with wide variation due to differing definitions of the condition (1). Compared with pain-free phases of their cycles, those suffering from dysmenorrhea experience reduced quality of life, poor mood, and decreased sleep during menstruation (1). Gastrointestinal symptoms also
<ol> <li>59</li> <li>60</li> <li>61</li> <li>62</li> <li>63</li> <li>64</li> <li>65</li> <li>66</li> <li>67</li> <li>68</li> </ol>	Background: Although a shared experience by women and people who menstruate throughout the world, menstruation represents an area of health often ignored and misunderstood by both patients and healthcare providers. While many individuals experience menstruation without significant symptoms, others endure pain and many other somatic, gastrointestinal, and mood symptoms which vary throughout the cycle. Dysmenorrhea affects 45-95% of menstruating individuals, with wide variation due to differing definitions of the condition (1). Compared with pain-free phases of their cycles, those suffering from dysmenorrhea experience reduced quality of life, poor mood, and decreased sleep during menstruation (1). Gastrointestinal symptoms also vary throughout the menstrual cycle, with one-third of women experiencing symptoms during

#### Ainsworth et al, 4

70	Additionally, irritability and mood swings can affect 22-40% of women, more often
71	before menstruation (4). As it relates to symptom co-occurrence, individuals with mood
72	symptoms like depression and anxiety are more likely to experience multiple gastrointestinal
73	symptoms both before and during menstruation (5). Despite improved standardization in
74	terminology and increasing prioritization of women's health issues, these symptoms are under
75	reported (6-8). Importantly, menstrual symptoms may present a significant impairment to
76	productivity and quality of life (9).

A recent review highlighted challenges in the field of menstrual health research (10). These challenges include how and from whom data is collected, normalization of symptoms, stigma regarding menstrual disorders, lack of standardized assessment tools, and differing cultural perceptions of this physiologic process (10–13). Previous studies of symptom prevalence and variation throughout the menstrual cycle are small prospective or survey studies (4,5). Given these limitations, there remain gaps in our knowledge of patient symptoms and opportunities for further study.

The emerging availability of mobile applications (apps) and user-reported data provides a novel approach to population health, in this instance, menstrual symptomatology, through 'digital epidemiology' (14–16). The impact of digital epidemiology to inform our understanding of population norms in menstrual health recently demonstrated a luteal phase length of  $12.4 \pm 2$ days (17). These results differ from the classical teaching of a conserved 14-day luteal phase (17).

In this study, through in-app user-reported data, we aim to report a population-based
assessment of symptomatology throughout the menstrual cycle. Specific objectives include

### Ainsworth et al, 5

92 describing the frequency of symptoms reported in each phase of the menstrual cycle and analysis93 of the relationship between symptoms.

## 94 Methods:

This cohort study includes active users of the Flo app recording symptoms during an ovulatory
cycle starting between January 1, 2021, and January 1, 2023. Users aged 18-45, not pregnant,
and actively involved in the app (reporting at least three menstrual cycles) were included.
Menstrual cycles between 21-35 days, menstrual bleeding between 1-10 days, follicular and
luteal phase lengths of at least five days each, positive ovulation predictor kit use, and at least
one self-reported menstrual symptom at any point in the cycle were included as 'normal'
menstrual cycles.

102 Cycle dates and phases were calculated based on user-provided data. Users report the start and end dates of their period and the date of positive ovulation test. Each cycle start date is 103 defined as the first day of bleeding. The mid-follicular phase was defined as the day after the last 104 105 day of menstrual bleeding until the start of the fertile window (Figure 1). An individual with less than five days between the end of menstrual bleeding and the day of ovulation had no defined 106 mid-follicular phase. The fertile window was calculated as the five days preceding ovulation and 107 the day of ovulation was estimated as the day following a user-reported positive ovulation 108 109 predictor kit. The luteal phase was split evenly in half and described as the early luteal phase and 110 the late luteal phase.

Symptoms were self-reported and associated with the phase of the menstrual cycle as
defined above. We classified symptoms into five groups: somatic (cramps, tender breasts,
headache, fatigue, backache, acne), gastrointestinal (GI) (bloating, nausea, diarrhea, cravings,

Ainsworth et al, 6

114	constipation), positive mood (happy, high sex drive, energetic), negative mood (mood swings,
115	anxious, depressed, insomnia, stress, obsessive thoughts), and discharge (creamy, eggwhite,
116	sticky, watery). Users could record as many symptoms in each category as desired each day.
117	Individual characteristics were matched to each cycle. Age at the time of the cycle was
118	based on the user's birthdate and cycle dates. A user's country was assigned based on phone
119	settings at app installation. Where the country at app installation was unavailable, country phone
120	settings at the last login was used. Country prevalence of symptoms was evaluated only when
121	100 users or more were included.

## 122 Statistical Methods

Using a cycle-level unit of analysis, we employed descriptive statistics to describe cycle 123 124 length and symptoms experienced overall and by phase. For cycles with a length of 25-30 days, we describe symptoms experienced by day of the cycle, where day 1 is the first day of bleeding. 125 126 We examined the correlation between all possible pairs of symptoms using a cycle-level unit of 127 analysis considering symptoms experienced at any point in the cycle. We reported Pearson 128 correlation coefficients for each possible pair. We also conducted a term frequency-inverse document frequency (tf-idf) analysis (18) for pairs of symptoms separately by cycle phase to 129 130 describe the frequency of pairs of any symptoms, taking into account the frequency of the individual symptoms that make up the pair. This is calculated as term frequency times inverse 131 document frequency, where term frequency is defined as the number of instances of a pair of 132 133 symptoms in a cycle phase, and inverse document frequency is defined as the logarithm of the 134 number of users logging one symptom from the pair during the relevant cycle phase divided by 135 the total number of symptoms logged in the phase. Data were analyzed in Python Jupyter 136 Notebook 6.0.1 and R version 4.2.0.

Ainsworth et al, 7

137	Results:
138	A total of 437,577 unique users and 896,051 unique, normal menstrual cycles met
139	inclusion criteria with an average of $2.05 \pm 1.8$ cycles per user (Figure 2). The mean age of users
140	was $30.0 \pm 5.4$ years; users under age 18 or over 45 were excluded from the analysis. Users were
141	included from 222 countries, with 113 countries having at least 100 users. The largest group of
142	users was in the United States (n=126,352), followed by Germany (n=45,018) and the United
143	Kingdom (n=35,007).
144	Of the 437,577 unique users included in this analysis (last cycle), the mean cycle length
145	was 28.4 $\pm$ 2.6 days (median 28.0 days), and the mean length of bleeding was 4.0 $\pm$ 1.1 days
146	(median 4.0 days). Most included cycles had a length of 25-31 days (75.7%, n =331,360),
147	followed by a length of $\geq$ 32 days (15.8%, n=69,479) and <25 days (8.4 %, n = 36,738).
148	Calculated from the predicted day of ovulation, the mean follicular phase length amongst users
149	was 14.4 $\pm$ 3.0 days (median 14.0 days), and the mean luteal phase length was 14.0 $\pm$ 2.7 days
150	(median 14.0 days).
151	Of the 896,051 unique cycles, somatic symptoms were reported most often; 88.3%
152	(n=790,923) of cycles reported at least one somatic symptom. Comparatively, gastrointestinal
153	symptoms and discharge symptoms were reported in $60.8\%$ of cycles each (n=545,107 and
154	544,460, respectively), negative mood symptoms were reported in 43.3% (n=388,249) of cycles,

and positive mood symptoms were reported in 35.4% (n=317,558). The type and frequency of
symptoms are shown in Figure 3. Menstrual cramps, breast tenderness, headache, and fatigue
were the most common symptoms reported.

Symptoms were next assessed by the menstrual cycle phase. Somatic, gastrointestinal,and negative mood symptoms were most frequent in the late luteal phase and least frequent in the

#### Ainsworth et al, 8

mid-follicular phase (Figure 4). 57.3% of all logged instances of tender breasts occurred during
the late luteal phase compared to 1.8% in the mid-follicular phase. Discharge and positive mood
symptoms were most common during the fertile window. 63.1% of all logged instances of egg
white discharge and 45.3% of all logged instances of high sex drive were during the fertile
window.

165 For cycles between 25-30 days in length (n=570,123 cycles), we examined daily 166 symptom logs for the three symptoms with the most variability per category (Figure 5). Overall, most symptoms are reported on day 1 of the cycle (436,812 symptoms logged from 211,021 167 168 cycles out of 570,123 total cycles); however, the fertile window is where most cycles have at 169 least one symptom logged. Out of 570,123 total cycles, 382,115 cycles had at least one symptom logged during the fertile window, and 283,652 had at least one symptom logged during the 170 171 bleeding days. The prevalence of somatic, gastrointestinal, and negative mood symptoms are highest on day 1 but decline quickly, reaching their lowest point around day 7 before slowly 172 173 increasing throughout the rest of the cycle. For positive mood symptoms, the prevalence of 174 energetic mood remains relatively stable throughout the cycle. In contrast, happy and high-sex-175 drive moods increase slowly in the early part of the cycle, peaking around day 14 of the cycle 176 and reaching baseline around day 20. Discharge symptoms are rarely logged during the early part of the cycle where bleeding occurs. Egg white discharge increases rapidly between days 6 and 13 177 before decreasing quickly to a low level by day 20. 178

For countries with at least 100 users, the number per country ranged from 103 in The Bahamas to 126,352 in the United States (Supplemental Table 1). The prevalence of cramps during the last cycle ranged from 30.5% in Vietnam to 74.6% in Iceland (Figure 6). Bloating

Ainsworth et al, 9

ranged from 17.6 in Thailand to 49.7% in Chile. Mood swings ranged from 13.3% in Hong Kongto 43.1% in Iraq.

Mood symptoms were most highly correlated with each other. The anxious mood was highly correlated with obsessive thoughts (r=0.60) and depressed mood (r=0.58). Depressed mood was correlated with obsessive thoughts (r=0.55), and happy mood was highly correlated with energetic mood (r=0.62, Figure 7). Similarly, fatigue was highly correlated with somatic and gastrointestinal symptoms such as bloating (r=0.62), headache (r=0.60), backache (r=0.58), and nausea (r=0.55).

A term frequency-inverse document frequency (tf-idf) analysis by cycle phase showed how pairs of symptoms correlate within cycle phases, adjusting for the frequency of individual symptoms (Figure 8 and Supplementary Tables 2 and 3). During the bleeding days and late luteal phase when cramps are common, the top five tf-idf values all included cramps, and cramps were most closely associated with nausea (tf-idf = 54,861 bleeding days, tf-idf = 68,467 late luteal). Happy and energetic were the top pair in the mid-follicular phase (tf-idf=23,333) and second in the fertile window (tf-idf=55,636).

197 Discussion:

In this study, we report the frequency of somatic, gastrointestinal, mood, and discharge symptoms experienced throughout the menstrual cycle by a cohort of global, ovulating periodtracking app users. Notably, most users were aged 30-34 and located in Europe and the United States. Our results build on prior work evaluating the menstrual cycle characteristics of women using period-tracking apps. The median cycle length, 28.8 days in our study, is consistent with previous studies and period tracking app data (17,19–22).

#### Ainsworth et al, 10

204 Somatic symptoms were reported most frequently, with cramps being the most reported 205 symptom. Somatic, gastrointestinal, and negative mood symptoms were more common in the late luteal phase than in the rest of the cycle. They reached a nadir in the mid-follicular phase 206 207 between bleeding and the fertile window/ovulation. The hormonal changes observed in the luteal phase may explain these findings. There is a direct correlation between the rapid rise of 208 progesterone, the dominant sex hormone in the luteal phase, and the abrupt increase in somatic 209 210 symptoms. Progesterone has been shown to influence breast changes and associated breast 211 tenderness in the luteal phase (23). By thermoregulatory actions, progesterone has also been 212 shown to impact circadian rhythms leading to decreased rapid eye movement (REM) sleep in the luteal phase and, thus a reported increase in fatigue (24). However, progesterone levels fall in the 213 week prior to menstruation while somatic symptoms continue to increase. Symptoms in the late 214 215 luteal phase reflect the effect of decreasing systemic sex steroid hormones. Pain disorders, such 216 as migraines and non-migraine headaches, have been shown to increase in the late luteal phase 217 when estradiol levels are lowest (25-27), in line with our findings of headaches being most 218 reported in this phase. These effects are modulated by estrogen effects on central pain processing networks and cerebral vasculature (26). Conversely, decreasing progesterone levels and the 219 220 resultant increase in available androgen receptors may explain the increase in acne reported in 221 the late luteal phase (28).

Gastrointestinal symptoms that increase throughout the luteal phase likely reflect multiple mechanisms (3). First, the effect of progesterone on serotonergic activity in both the central nervous system and the GI tract slows gastrointestinal motility leading to constipation in the early luteal phase (29). Second, increasing prostaglandin levels in the late luteal phase lead to

#### Ainsworth et al, 11

stimulation of smooth muscle contractions – leading to both uterine cramping and increased
gastrointestinal motility and associated diarrhea (30).

228 The effect of the menstrual cycle on mental health has been well studied, and 229 premenstrual mood disorders are well classified, with over 300 subtypes reported. Mood changes 230 in the luteal phase affect 50-80% of reproductive-aged women, although 3-8% of individuals 231 have such severe symptoms with associated functional impairments that they meet diagnostic 232 criteria in the DSM-V (31). Our study confirmed an increase in negative mood symptoms throughout the luteal phase, possibly reflecting known alterations in sex steroids and the 233 234 following neurotransmitters: serotonin, noradrenaline, and gamma-aminobutyric acid (GABA) 235 (31,32). Negative mood symptoms decreased throughout the follicular phase, with a 236 corresponding increase in positive mood symptoms that reached peak levels in the late follicular 237 phase. Positive mood symptom frequency in the follicular phase is consistent with prior studies 238 reporting individual well-being to be highest at this time in the cycle (33,34). Recent work 239 utilizing functional magnetic resonance imaging (fMRI) has added to our understanding. Sex 240 hormones appear to impact communication between brain regions, in addition to their known 241 impact on neurotransmitter secretion (35). This impacts cognition and emotional processing, 242 such that estrogen seems to decrease reaction to negative stimuli while progesterone seems to 243 increase emotional reactions to negative stimuli (36).

The relationship between mood and somatic symptoms during the menstrual cycle has been evaluated with mixed results. One study found an increase in mood symptoms in women with gastrointestinal symptoms, skin changes, breast changes, and abdominal bloating. At the same time, there was no effect of concurrent mood symptoms seen in women who reported back and joint pain (37). We found negative mood symptoms (depressed mood, mood swings, anxious

#### Ainsworth et al, 12

249	mood) co-occurred with cramps in the bleeding days and late luteal phase while positive mood
250	symptoms (energetic and happy) occurred together in the mid-follicular through early luteal
251	phases, without strong associations with somatic symptoms.
252	We found small geographic differences in user-reported symptoms during the menstrual
253	cycle. This may reflect the impact of knowledge or sociocultural constructs, which impact
254	individual perceptions of symptoms and their menstrual experience (38). Historically,
255	menstruation has been described negatively. Previous work has shown an association between
256	early menstrual/menarchal experiences and current menstrual experience, body perception, and
257	overall health (39-42). However, other studies examining symptom experience across broad
258	geographic regions have not found regional differences in symptoms (43).

The strength of this study lies in the number of unique users and in the large amount of 259 user-reported data from a global population. However, this study is not without limitations. 260 Specifically, this study is subject to selection bias as not all menstruating individuals choose to 261 262 use period-tracking apps. Demographic and other individual characteristic data were not 263 collected, including user-reported race and ethnicity, which may be important mediators of 264 menstrual symptom characteristics and experiences that may impact our results. We included 265 only ovulatory cycles where ovulation was confirmed by self-ovulation test to more accurately 266 divide the cycle into phases. Users logging ovulation tests likely have a goal of conception and 267 may thus have a different experience of menstrual symptoms and a difference in the tendency of 268 logging symptoms. Additionally, irregular and non-ovulatory cycles are not represented in this 269 analysis, and results are not generalizable to these populations. Although this study represents a 270 global menstruating population, many countries remain absent or underrepresented, presenting 271 an opportunity for future research. Other limitations include the use of self-reported symptom-

272	tracking data. Users log symptoms through the app but may not log symptoms consistently
273	throughout the cycle (e.g., potentially more likely to log symptoms when logging other events
274	such as ovulation or period) and may not log all symptoms experienced. Users also may be more
275	likely to log symptoms that appear at the top and front of the app over symptoms that appear
276	lower down or require scrolling to see. This decreases the representativeness of symptoms
277	recorded and limits our ability to compare results with other methods of symptom data
278	collection.
279	Conclusions:
280	Our study presents an expanded understanding of symptoms experienced during the
281	menstrual cycle. These findings reflect the value of population-level menstrual cycle data, which
282	can help inform individual patients and clinicians while strengthening research efforts and calls
283	for advocacy for Women's Health.
284 285	Abbreviations:
286	GI: gastrointestinal
287	Tf-idf: term frequency-inverse document frequency
288	REM: rapid eye movement
289	DSM-V: Diagnostic and Statistical Manual of Mental Disorders, 5th edition
290	GABA: gamma-aminobutyric acid
291	fMRI: functional magnetic resonance imaging
292	

## Ainsworth et al, 14

## 293 **Declarations:**

294	1.	IRB approval waived. Documentation attached as supporting document
295	2.	Consent for publication: Not applicable
296	3.	Availability of data and materials: The datasets used and/or analyzed during the current
297		study are available from the corresponding author on reasonable request.
298	4.	Competing interests:
299		KP: Flo Health UK Limited (Employment, ownership interest, stock/stock options)
300		RB: Flo Health UK Limited (Employment)
301		LZ: Flo Health UK Limited (Employment, ownership interest, stock/stock options)
302		RS: Flo Health UK Limited (Employment, ownership interest, stock/stock options)
303		CP: Flo Health UK Limited (Employment)
304		AW: Flo Health UK Limited (Employment, ownership interest, stock/stock options)
305		AC: Flo Health UK Limited (Employment)
306		FG: Flo Health UK Limited (Employment)
307		SP: Flo Health UK Limited (Employment, ownership interest, stock/stock options).
308		Other authors did not report any potential conflicts of interest.
309	5.	Author contributions:
310		AJA: Design, interpretation of data, drafted and substantially revised work
311		KP: Design; acquisition, analysis, and interpretation of data; drafted and substantially
312		revised work

Ainsworth et al, 15

313		RB: Acquisition, analysis, and interpretation of data
314		LZ: Design, interpretation of data, and substantively revised work
315		RS: Design; acquisition, analysis, and interpretation of data
316		CP: Analysis and interpretation of data
317		AW: Acquisition, analysis, and interpretation of data
318		AC: Acquisition, analysis, and interpretation of data
319		FG: Analysis and interpretation of data
320		SP: Interpretation of data and substantively revised work
321		SB: Design, interpretation of data, substantially revised work
322	6.	Acknowledgements: None

#### References 323

- 3241. Lacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today: a critical
- 325 review. Hum Reprod Update. 2015 Nov 1;21(6):762-78.
- Moore J, Barlow D, Jewell D, Kennedy S. Do gastrointestinal symptoms vary with the menstrual 3262.
- 327 cycle? Br J Obstet Gynaecol. 1998 Dec;105(12):1322-5.
- 3283. Judkins TC, Dennis-Wall JC, Sims SM, Colee J, Langkamp-Henken B. Stool frequency and
- form and gastrointestinal symptoms differ by day of the menstrual cycle in healthy adult women 329
- 330 taking oral contraceptives: a prospective observational study. BMC Womens Health. 2020 Jun 331 29;20(1):136.
- 3324. Lete I, Häusler G, Pintiaux A, Jamin C, Nappi RE, Fiala C, et al. The inconvenience due to
- women's monthly bleeding (ISY) survey: a study of premenstrual symptoms among 5728 333
- 334 women in Europe. Eur J Contracept Reprod Health Care Off J Eur Soc Contracept. 2017 Oct;22(5):354-9. 335
- 3365. Bernstein MT, Graff LA, Avery L, Palatnick C, Parnerowski K, Targownik LE. Gastrointestinal
- 337 symptoms before and during menses in healthy women. BMC Womens Health. 2014 Jan 338 22;14:14.
- Chen CX, Draucker CB, Carpenter JS. What women say about their dysmenorrhea: a qualitative 3396. 340 thematic analysis. BMC Womens Health. 2018 Mar 2;18(1):47.
- Chen CX, Kwekkeboom KL, Ward SE. Beliefs About Dysmenorrhea and Their Relationship to 3417. Self-Management. Res Nurs Health. 2016 Aug;39(4):263-76. 342
- Ramos-Pichardo JD, Ortega-Galán ÁM, Iglesias-López MT, Abreu-Sánchez A, Fernández-3438.
- Martínez E. Why Do Some Spanish Nursing Students with Menstrual Pain Fail to Consult 344
- Healthcare Professionals? Int J Environ Res Public Health. 2020 Nov 5;17(21):E8173. 345

- 3469. Schoep ME, Adang EMM, Maas JWM, De Bie B, Aarts JWM, Nieboer TE. Productivity loss
- due to menstruation-related symptoms: a nationwide cross-sectional survey among 32 748
- 348 women. BMJ Open. 2019 Jun 27;9(6):e026186.
- 34910. Critchley HOD, Babayev E, Bulun SE, Clark S, Garcia-Grau I, Gregersen PK, et al.
- Menstruation: science and society. Am J Obstet Gynecol. 2020 Nov;223(5):624–64.
- 35111. Matteson KA, Zaluski KM. Menstrual Health as a Part of Preventive Health Care. Obstet
- 352 Gynecol Clin North Am. 2019 Sep;46(3):441–53.
- 35312. Chen CX, Shieh C, Draucker CB, Carpenter JS. Reasons women do not seek health care for dysmenorrhea. J Clin Nurs. 2018 Jan;27(1–2):e301–8.
- 35513. Tan DA, Haththotuwa R, Fraser IS. Cultural aspects and mythologies surrounding menstruation and abnormal uterine bleeding. Best Pract Res Clin Obstet Gynaecol. 2017 Apr;40:121–33.
- 35714. Symul L, Wac K, Hillard P, Salathé M. Assessment of menstrual health status and evolution through mobile apps for fertility awareness. NPJ Digit Med. 2019;2:64.
- 35915. Mao L, Xi S, Bai W, Yao C, Zhou Y, Chen X, et al. Menstrual patterns and disorders among
- Chinese women of reproductive age: A cross-sectional study based on mobile application data.Medicine (Baltimore). 2021 Apr 23;100(16):e25329.
- 36216. Karasneh RA, Al-Azzam SI, Alzoubi KH, Muflih SM, Hawamdeh SS. Smartphone Applications
- for Period Tracking: Rating and Behavioral Change among Women Users. Obstet Gynecol Int.
   2020;2020;2192387.
- 36517. Bull JR, Rowland SP, Scherwitzl EB, Scherwitzl R, Danielsson KG, Harper J. Real-world
- menstrual cycle characteristics of more than 600,000 menstrual cycles. NPJ Digit Med.
  2019;2:83.
- 36818. Leskovec J, Rajaraman A, Ullman JD. Mining of Massive Data Sets. Cambridge UniversityPress; 2020. 566 p.
- 37019. Li K, Urteaga I, Wiggins CH, Druet A, Shea A, Vitzthum VJ, et al. Characterizing physiological
- and symptomatic variation in menstrual cycles using self-tracked mobile-health data. NPJ Digit
   Med. 2020;3:79.
- 37320. Najmabadi S, Schliep KC, Simonsen SE, Porucznik CA, Egger MJ, Stanford JB. Menstrual
- bleeding, cycle length, and follicular and luteal phase lengths in women without known
- subfertility: A pooled analysis of three cohorts. Paediatr Perinat Epidemiol. 2020
- 376 May;34(3):318–27.
- 37721. Li K, Urteaga I, Shea A, Vitzthum VJ, Wiggins CH, Elhadad N. A predictive model for next
- 378 cycle start date that accounts for adherence in menstrual self-tracking. J Am Med Inform Assoc
  379 JAMIA. 2021 Dec 28;29(1):3–11.
- 38022. Broad A, Biswakarma R, Harper JC. A survey of women's experiences of using period tracker applications: Attitudes, ovulation prediction and how the accuracy of the app in predicting period
- start dates affects their feelings and behaviours. Womens Health Lond Engl. 2022
- 383 Dec;18:17455057221095246.
- 38423. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev. 1997
   Aug;18(4):502–19.
- 38624. Shechter A, Varin F, Boivin DB. Circadian variation of sleep during the follicular and luteal
  phases of the menstrual cycle. Sleep. 2010 May;33(5):647–56.
- 38825. LeResche L, Mancl L, Sherman JJ, Gandara B, Dworkin SF. Changes in temporomandibular
  pain and other symptoms across the menstrual cycle. Pain. 2003 Dec;106(3):253–61.
- 39026. Sacco S, Ricci S, Degan D, Carolei A. Migraine in women: the role of hormones and their
- impact on vascular diseases. J Headache Pain. 2012 Apr;13(3):177–89.

- 39227. Stening K, Eriksson O, Wahren L, Berg G, Hammar M, Blomqvist A. Pain sensations to the cold pressor test in normally menstruating women: comparison with men and relation to menstrual
- 393
- phase and serum sex steroid levels. Am J Physiol Regul Integr Comp Physiol. 2007 394
- 395 Oct;293(4):R1711-1716.
- 39628. Raghunath RS, Venables ZC, Millington GWM. The menstrual cycle and the skin. Clin Exp Dermatol. 2015 Mar;40(2):111-5. 397
- 39829. Xiao ZL, Pricolo V, Biancani P, Behar J. Role of progesterone signaling in the regulation of G-
- protein levels in female chronic constipation. Gastroenterology. 2005 Mar;128(3):667-75. 399
- 40030. Evans J, Salamonsen LA. Inflammation, leukocytes and menstruation. Rev Endocr Metab 401 Disord. 2012 Dec;13(4):277-88.
- 40231. Ryu A, Kim TH. Premenstrual syndrome: A mini review. Maturitas. 2015 Dec;82(4):436-40.
- 40332. Toffol E, Kalleinen N, Urrila AS, Himanen SL, Porkka-Heiskanen T, Partonen T, et al. The
- relationship between mood and sleep in different female reproductive states. BMC Psychiatry. 404 2014 Jun 16;14:177. 405
- 40633. Sanders D, Warner P, Bäckström T, Bancroft J. Mood, sexuality, hormones and the menstrual
- cycle. I. Changes in mood and physical state: description of subjects and method. Psychosom 407 408 Med. 1983 Dec;45(6):487-501.
- 40934. Meaden PM, Hartlage SA, Cook-Karr J. Timing and severity of symptoms associated with the
- menstrual cycle in a community-based sample in the Midwestern United States. Psychiatry Res. 410
- 411 2005 Mar 30;134(1):27-36.
- 41235. Toffoletto S, Lanzenberger R, Gingnell M, Sundström-Poromaa I, Comasco E. Emotional and
- cognitive functional imaging of estrogen and progesterone effects in the female human brain: a 413 systematic review. Psychoneuroendocrinology. 2014 Dec;50:28-52. 414
- 41536. Sakaki M, Mather M. How reward and emotional stimuli induce different reactions across the menstrual cycle. Soc Personal Psychol Compass. 2012 Jan 1;6(1):1–17. 416
- 41737. Kiesner J, Pastore M. Day-to-day co-variations of psychological and physical symptoms of the
- menstrual cycle: insights to individual differences in steroid reactivity. 418
- 419 Psychoneuroendocrinology. 2010 Apr;35(3):350-63.
- 42038. Marván ML, Escobedo C. Premenstrual symptomatology: role of prior knowledge about premenstrual syndrome. Psychosom Med. 1999 Apr;61(2):163-7. 421
- 42239. McPherson ME, Korfine L. Menstruation across time: menarche, menstrual attitudes,
- 423 experiences, and behaviors. Womens Health Issues Off Publ Jacobs Inst Womens Health. 2004 424 Dec;14(6):193-200.
- 42540. Stubbs ML. Cultural perceptions and practices around menarche and adolescent menstruation in the United States. Ann N Y Acad Sci. 2008;1135:58-66. 426
- 42741. Padmanabhanunni A, Jaffer L, Steenkamp J. Menstruation experiences of South African women belonging to the ama-Xhosa ethnic group. Cult Health Sex. 2018 Jun;20(6):704–14. 428
- 42942. Barrington DJ, Robinson HJ, Wilson E, Hennegan J. Experiences of menstruation in high
- 430 income countries: A systematic review, qualitative evidence synthesis and comparison to low-
- 431 and middle-income countries. PloS One. 2021;16(7):e0255001.
- Dennerstein L, Lehert P, Heinemann K. Global epidemiological study of variation of 432 43.
- premenstrual symptoms with age and sociodemographic factors. Menopause Int. 2011 433
- Sep:17(3):96-101. 434









Cramps	Bloating



Mood swings







	4 <sub>Che</sub>	Anxious	Bachache	Bloating	Constitution	Cramps	Cia <sub>luigos</sub>	Creamy Discriage	Depressed	Diarrh <sub>ea</sub>	Eggunnie Discherge	Energen,	Faligue	Happy	headache	High Set Drive	Insonnia	Mood Surings	Nalusea	Osessite house	Stick Discharge	Stress	<sup>Tender</sup> Br <sub>easts</sub>	Watery Discharge
Acne																								
Anxious	0.35																							
Backache	0.41	0.35																						
Bloating	0.45	0.39	0.51																					
Constipation	0.34	0.29	0.38	0.48																				
Cramps	0.35	0.29	0.5	0.49	0.33																			
Cravings	0.38	0.34	0.39	0.48	0.35	0.33																		
Creamy Discharge	0.33	0.26	0.34	0.38	0.27	0.38	0.27																	
Depressed	0.31	0.58	0.31	0.32	0.26	0.25	0.3	0.21																
Diarrhea	0.27	0.24	0.32	0.35	0.24	0.32	0.26	0.23	0.2															
Eggwhite Discharge	0.25	0.2	0.27	0.29	0.22	0.31	0.21	0.4	0.16	0.18														
Energetic	0.26	0.27	0.23	0.28	0.2	0.21	0.27	0.3	0.19	0.18	0.24													
Fatigue	0.48	0.45	0.58	0.62	0.43	0.49	0.48	0.4	0.37	0.37	0.31	0.29												
Нарру	0.3	0.29	0.28	0.32	0.22	0.27	0.27	0.39	0.18	0.21	0.28	0.62	0.37											
Headache	0.44	0.37	0.54	0.49	0.36	0.49	0.38	0.35	0.33	0.32	0.28	0.25	0.6	0.31										
High Sex Drive	0.24	0.23	0.27	0.27	0.21	0.25	0.29	0.27	0.2	0.18	0.23	0.3	0.3	0.32	0.27									
Insomnia	0.32	0.34	0.36	0.4	0.36	0.3	0.38	0.24	0.31	0.27	0.19	0.2	0.46	0.2	0.37	0.21								
Mood Swings	0.4	0.46	0.42	0.44	0.32	0.36	0.42	0.34	0.44	0.26	0.26	0.3	0.5	0.31	0.44	0.31	0.35							
Nausea	0.33	0.3	0.47	0.46	0.34	0.47	0.35	0.29	0.27	0.33	0.23	0.18	0.55	0.22	0.5	0.25	0.33	0.36						
Obsessive Thoughts	0.29	0.6	0.3	0.32	0.26	0.22	0.33	0.2	0.55	0.19	0.16	0.22	0.36	0.21	0.3	0.2	0.3	0.42	0.25					
Sticky Discharge	0.29	0.24	0.28	0.32	0.23	0.3	0.24	0.43	0.19	0.19	0.33	0.26	0.34	0.33	0.3	0.23	0.21	0.29	0.23	0.19				
Stress	0.29	0.47	0.28	0.28	0.22	0.2	0.27	0.2	0.4	0.19	0.15	0.19	0.34	0.2	0.3	0.19	0.27	0.38	0.2	0.43	0.19			
Tender Breasts	0.32	0.22	0.39	0.4	0.28	0.46	0.3	0.33	0.19	0.23	0.27	0.2	0.42	0.23	0.39	0.22	0.25	0.31	0.38	0.17	0.26	0.15		
Watery Discharge	0.25	0.22	0.29	0.31	0.23	0.31	0.23	0.37	0.17	0.21	0.33	0.23	0.32	0.28	0.29	0.22	0.2	0.27	0.26	0.17	0.27	0.16	0.26	





# Percentage of symptom occurrence during each phase